Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Jakob W. Gotfredsen | M | - |
Neurokey A/S
 Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | 3 jaar |
| Jesper Alling Coverdale Kofoed | M | - |
University of Copenhagen
| 7 jaar |
| Christian Torp-Pedersen | M | - |
Neurokey A/S
Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | 3 jaar |
| Martin Jensen | M | 64 |
University of Copenhagen
| 10 jaar |
| Lars Kober | M | - |
Neurokey A/S
Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | 3 jaar |
| Jesper Vestergaard | M | - |
University of Copenhagen
| 6 jaar |
| Henrik Hardboe Galsgaard | M | 54 |
University of Copenhagen
| 1 jaar |
| Jesper Brøndum | M | 55 |
University of Copenhagen
| 3 jaar |
| Caspar Rose | M | 53 |
University of Copenhagen
| 3 jaar |
| Thomas Tscherning | M | - |
University of Copenhagen
| 3 jaar |
| Mikkel Falkenberg | M | - |
University of Copenhagen
| 1 jaar |
| Lida Skifte Lennert | F | 52 |
University of Copenhagen
| - |
| Soren Mogelsvang | M | 52 |
University of Copenhagen
| 1 jaar |
| Hanne Andersen | F | - |
University of Copenhagen
| 4 jaar |
| Lars Waalen Sandberg | M | 54 |
University of Copenhagen
| 1 jaar |
| Thomas Hinrichsen | M | 49 |
University of Copenhagen
| 6 jaar |
| Jacob Hübertz | M | - |
University of Copenhagen
| 6 jaar |
| Helle Thorning-Schmidt | F | 57 |
University of Copenhagen
| 7 jaar |
| Anders Thange Nordlund | M | - |
University of Copenhagen
| 4 jaar |
| Torsten Lodberg Smed | M | 54 |
University of Copenhagen
| 5 jaar |
| Christian Skakkebæk | M | - |
University of Copenhagen
| 6 jaar |
| Anja E. H. Holm | M | 59 |
University of Copenhagen
| 3 jaar |
| Lars Friis Mikkelsen | M | 56 |
University of Copenhagen
| 3 jaar |
| Kresten Buch | M | - |
University of Copenhagen
| 5 jaar |
| Mikkel Hemmingsen | M | - |
University of Copenhagen
| 1 jaar |
| Torsten Steenholt | M | 55 |
University of Copenhagen
| 6 jaar |
| Steen Jørgensen | M | - |
University of Copenhagen
| 7 jaar |
| Hans Tino Hansen | M | 55 |
University of Copenhagen
| 1 jaar |
| Martin Lange | M | 54 |
University of Copenhagen
| 3 jaar |
| Atilla Olesen | M | - |
University of Copenhagen
| 6 jaar |
| Malene Lei Raben | F | - |
University of Copenhagen
| 3 jaar |
| Christian Grane | M | - |
University of Copenhagen
| 4 jaar |
| Jesper Gromada | M | - |
University of Copenhagen
| 3 jaar |
| Craig Watkins | M | - |
University of Copenhagen
| - |
| Torben Winther Kristensen | M | - |
University of Copenhagen
| 1 jaar |
| Ken Belanger | M | - |
University of Copenhagen
| 1 jaar |
| Rasmus Lund | M | 50 |
University of Copenhagen
| 5 jaar |
| Nicholas Gregoire | M | - |
University of Copenhagen
| 4 jaar |
| Peter Bisgaard | M | 50 |
Neurokey A/S
Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | - |
| Kim Lennart Dueholm | M | 61 |
University of Copenhagen
| 3 jaar |
| Peter Moldt | M | 65 |
Neurokey A/S
Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | - |
| Carl Bek-Nielsen | M | 51 |
University of Copenhagen
| 4 jaar |
| Martin Lauge Bek-Nielsen | M | 49 |
University of Copenhagen
| 4 jaar |
| Carsten Schou | M | - |
Neurokey A/S
Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | - |
| Christian René Tang-Jespersen | M | 55 |
University of Copenhagen
| 5 jaar |
| Frank Knudsen | M | 66 |
Neurokey A/S
Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | - |
| Mads Buhl Axelsen | M | 66 |
Neurokey A/S
Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | - |
| Stephen Alstrup | M | - |
University of Copenhagen
| 3 jaar |
| Nikolai Søren Kirkby | M | - |
University of Copenhagen
| 3 jaar |
| Ole Sibbesen | M | - |
University of Copenhagen
| 3 jaar |
| Manuel Lopez-Figueroa | M | - |
University of Copenhagen
| 5 jaar |
| Jesper Nerlov | M | 56 |
University of Copenhagen
| 3 jaar |
| Per Ove Kogut | M | 60 |
University of Copenhagen
| - |
| Charlotte Videbaek | M | 62 |
Neurokey A/S
Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | 2 jaar |
| Peter Lindberg | M | - |
University of Copenhagen
| 4 jaar |
| Henrik N. Rasmussen | M | - |
University of Copenhagen
| 3 jaar |
| David Helgason | M | 46 |
University of Copenhagen
| 4 jaar |
| Lykke Friis | M | 54 |
University of Copenhagen
| 3 jaar |
| Zhan Li | M | 62 |
University of Copenhagen
| 2 jaar |
| Casper Bych | M | 52 |
University of Copenhagen
| 3 jaar |
| Barbara Plucnar Jensen | F | 53 |
University of Copenhagen
| 1 jaar |
| Amar A. Sethi | M | - |
University of Copenhagen
| 3 jaar |
| Claus Christensen | M | 60 |
University of Copenhagen
| 3 jaar |
| Jesper Nielsen | M | 55 |
University of Copenhagen
| 1 jaar |
| Jakob Riis | M | 58 |
University of Copenhagen
| 3 jaar |
| Finn Eggert Sørensen | M | 70 |
Neurokey A/S
Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | - |
| Adam Erritzøe | M | - |
University of Copenhagen
| 5 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Denemarken | 67 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Uno Jakob Weber
- Persoonlijk netwerk
